Akèy › Kansè san › New York › New York City
Etid klinik pou Kansè san nan New York City, NY
26 etid pou Kansè san ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Ap rekriteFaz 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0032), New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Ap rekriteFaz 1
- NYU Langone Health, New York
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 2
- Mount Sinai Medical Center, New York
Genomic Profiling in Cancer Patients
Ap rekriteEtid obsèvasyon
- Metropolitan Hospital Center, New York
- Ralph Lauren Center for Cancer Care and Prevention, New York
- Memorial Sloan Kettering Cancer Center, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- David H. Koch Center for Cancer Care, New York
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Ap rekriteFaz 1/2
- Research Site, New York
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
- Weill Cornell Medical Center, New York
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College-NY Presbyterian Hospital, New York
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
Ap rekriteVolontè an sante akeyi
- NYP/Weill Cornell Medical Center, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- New York University Langone Medical Center, New York
- New York Presbyterian Hospital at Cornell, New York
- Mount Sinai Medical Center - New York, New York
- ak 3 plis
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Ap rekriteFaz 2
- New York University (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
IVIG for Infection Prevention After CAR-T-Cell Therapy
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Ap rekriteFaz 3
- New York Presbyterian Hospital, New York
- Mt Sinai Medical Center, New York
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Ap rekriteEtid obsèvasyon
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Ap rekriteVolontè an sante akeyi
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Mt Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- New York - Presbyterian / Weill Cornell Medicine, New York
- Mount Sinai - Ruttenberg Treatment Center, New York
- Columbia University Medical Center, New York
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Ap rekriteEtid obsèvasyon
- Memorial Sloan Kettering Cancer Center, New York
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Ap rekriteFaz 1
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
Etid Kansè san nan lòt vil
- Houston, TX46 etid
- Boston, MA25 etid
- Washington, DC19 etid
- Seattle, WA18 etid
- Baltimore, MD18 etid
- Los Angeles, CA17 etid
- Durham, NC16 etid
- Chicago, IL15 etid
- Philadelphia, PA14 etid
- Nashville, TN13 etid
- Columbus, OH13 etid
- Edison, NJ13 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.